Published in PLoS One on February 05, 2009
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev (2011) 5.15
Drug-Resistant Malaria: The Era of ACT. Curr Infect Dis Rep (2010) 1.33
Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J (2010) 1.10
Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int J Parasitol (2010) 1.10
Heritability of the human infectious reservoir of malaria parasites. PLoS One (2010) 1.00
Sub-microscopic gametocyte carriage in febrile children living in different areas of Gabon. Malar J (2013) 0.96
A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission. Malar J (2014) 0.89
Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012. Malar J (2014) 0.85
Fitness components and natural selection: why are there different patterns on the emergence of drug resistance in Plasmodium falciparum and Plasmodium vivax? Malar J (2013) 0.81
Inclusion of gametocyte parameters in anti-malarial drug efficacy studies: filling a neglected gap needed for malaria elimination. Malar J (2015) 0.79
Low-grade sulfadoxine-pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, Angola. Malar J (2016) 0.75
Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis (2002) 5.75
Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis (2003) 5.21
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J (2007) 4.85
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis (1997) 4.66
Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg (2007) 4.20
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol (1998) 3.43
Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis (2006) 3.17
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother (2006) 3.10
Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. Trop Med Int Health (2007) 2.69
Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother (2000) 2.68
Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother (2003) 2.57
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis (2007) 2.44
Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis (2006) 2.26
Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg (2002) 2.25
Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol (2005) 2.22
Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol (2004) 2.16
Host genotype by parasite genotype interactions underlying the resistance of anopheline mosquitoes to Plasmodium falciparum. Malar J (2005) 1.99
Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J Infect Dis (2005) 1.99
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis (2007) 1.99
Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis (2008) 1.96
Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol (2005) 1.96
Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol (1989) 1.87
Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol (2007) 1.84
Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study. Malar J (2007) 1.81
Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg (2003) 1.78
(Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate. Int J Parasitol (2006) 1.75
Cultivation of fertile Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures. Trans R Soc Trop Med Hyg (1982) 1.71
Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother (2004) 1.71
Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother (2005) 1.69
Chloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials (2006) 1.69
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health (2004) 1.56
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am J Epidemiol (2002) 1.48
Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health (2005) 1.46
Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum isolates from India and Thailand: a molecular epidemiologic study. Trop Med Int Health (2000) 1.35
Age-dependent distribution of Plasmodium falciparum gametocytes quantified by Pfs25 real-time QT-NASBA in a cross-sectional study in Burkina Faso. Am J Trop Med Hyg (2007) 1.34
Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg (2003) 1.30
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. Am J Trop Med Hyg (2007) 1.13
Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area. Ann Trop Med Parasitol (2001) 1.10
Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis (2003) 1.09
Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health (2003) 1.07
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. Am J Trop Med Hyg (2002) 1.06
Use of area under the curve to characterize transmission potential after antimalarial treatment. Am J Trop Med Hyg (2006) 1.03
Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malar J (2007) 1.00
Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Trans R Soc Trop Med Hyg (2008) 1.00
The genetic structure and history of Africans and African Americans. Science (2009) 10.65
Convergent adaptation of human lactase persistence in Africa and Europe. Nat Genet (2006) 9.44
Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med (2010) 5.71
Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature (2002) 5.48
Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun (2012) 5.34
Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med (2012) 4.68
Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg (2007) 4.20
High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol (2005) 3.95
Eradication of Anopheles gambiae from Brazil: lessons for malaria control in Africa? Lancet Infect Dis (2002) 3.79
Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med (2013) 3.23
Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis (2006) 3.17
Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J (2008) 3.02
Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet (2011) 2.98
Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One (2009) 2.94
Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One (2009) 2.87
A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem (2003) 2.84
Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya. Malar J (2004) 2.84
Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med (2008) 2.78
Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. Trop Med Int Health (2007) 2.69
Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J (2008) 2.68
The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol (2006) 2.53
Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A (2005) 2.49
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One (2009) 2.49
Highly sensitive detection of malaria parasitemia in a malaria-endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. J Infect Dis (2013) 2.41
Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. J Immunol (2002) 2.39
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Independent introduction of two lactase-persistence alleles into human populations reflects different history of adaptation to milk culture. Am J Hum Genet (2008) 2.28
Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One (2009) 2.18
Serological markers suggest heterogeneity of effectiveness of malaria control interventions on Bioko Island, equatorial Guinea. PLoS One (2011) 2.18
Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. Elife (2013) 2.17
Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One (2007) 2.17
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother (2010) 2.15
The human malaria parasite Pfs47 gene mediates evasion of the mosquito immune system. Science (2013) 2.15
Improved synchronous production of Plasmodium falciparum gametocytes in vitro. Mol Biochem Parasitol (2007) 2.06
Host genotype by parasite genotype interactions underlying the resistance of anopheline mosquitoes to Plasmodium falciparum. Malar J (2005) 1.99
Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis (2004) 1.99
Proteomic profiling of Plasmodium sporozoite maturation identifies new proteins essential for parasite development and infectivity. PLoS Pathog (2008) 1.98
The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS One (2011) 1.95
Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health (2004) 1.93
Is the current decline in malaria burden in sub-Saharan Africa due to a decrease in vector population? Malar J (2011) 1.91
Determination of the processes driving the acquisition of immunity to malaria using a mathematical transmission model. PLoS Comput Biol (2007) 1.87
Mitochondrial DNA targets increase sensitivity of malaria detection using loop-mediated isothermal amplification. J Clin Microbiol (2010) 1.87
Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J (2008) 1.86
(Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate. Int J Parasitol (2006) 1.75
Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. J Infect Dis (2013) 1.73
Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility. PLoS Pathog (2010) 1.72
Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother (2004) 1.71
Chloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials (2006) 1.69
Geographic structure of Plasmodium vivax: microsatellite analysis of parasite populations from Sri Lanka, Myanmar, and Ethiopia. Am J Trop Med Hyg (2010) 1.69
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J (2008) 1.69
Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS One (2009) 1.68
Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg (2004) 1.65
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials (2006) 1.65
No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg (2006) 1.64
Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities. Int J Parasitol (2011) 1.64
Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A (2008) 1.64
Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J (2013) 1.64
Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One (2012) 1.64
Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection. J Infect Dis (2009) 1.63
Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol (2007) 1.63
Structural diversity and African origin of the 17q21.31 inversion polymorphism. Nat Genet (2012) 1.62
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
The suitability of clay pots for indoor sampling of mosquitoes in an arid area in northern Tanzania. Acta Trop (2009) 1.62
Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis (2013) 1.61
Change in composition of the Anopheles gambiae complex and its possible implications for the transmission of malaria and lymphatic filariasis in north-eastern Tanzania. Malar J (2012) 1.59
Accuracy of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in an area with declining malaria burden in north-eastern Tanzania. Malar J (2011) 1.59
Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis (2007) 1.58
Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One (2012) 1.57
Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J (2013) 1.57
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A (2013) 1.57
Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J Infect Dis (2012) 1.54
Dynamic histone H3 epigenome marking during the intraerythrocytic cycle of Plasmodium falciparum. Proc Natl Acad Sci U S A (2009) 1.54
Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis (2013) 1.52
Evidence of still-ongoing convergence evolution of the lactase persistence T-13910 alleles in humans. Am J Hum Genet (2007) 1.51
Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog (2011) 1.51
Interferon-γ--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. J Leukoc Biol (2010) 1.51
Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria. Malar J (2008) 1.51
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51